Stock Code: 002750 Stock Abbreviation: *ST Longjin Announcement No.: 2025-044
Kunming Longjin Pharmaceutical Co., Ltd. announces the risk warning regarding the suspension of its stock and possible delisting. The company and all members of the board guarantee that the information disclosed is true, accurate, and complete, without false records, misleading statements, or significant omissions.
Special Reminder: Kunming Longjin Pharmaceutical Co., Ltd. (hereinafter referred to as "the Company") may face delisting after the disclosure of its 2024 annual report, as the audited total profit, net profit, and net profit after deducting non-recurring gains and losses for the year 2024 are all negative, and the revenue after deductions is below 300 million yuan. According to Article 9.3.12 of the "Shenzhen Stock Exchange Stock Listing Rules (2024 Revision)" (hereinafter referred to as "Listing Rules"), the Company's stock will be delisted from the Shenzhen Stock Exchange. According to Article 9.3.13 of the "Listing Rules," if a listed company encounters any of the situations specified in Article 9.3.12, it must disclose a risk warning announcement regarding the possible delisting of its stock simultaneously with the annual report. The Company's stock will be suspended from trading starting April 25, 2025.
Reasons for Possible Delisting
The Company disclosed its "2024 Annual Report" (Announcement No.: 2025-033) on April 24, 2025, indicating that the audited total profit, net profit, and net profit after deducting non-recurring gains and losses for the year 2024 are all negative, and the revenue after deductions is below 300 million yuan. According to Article 9.3.12 of the "Listing Rules," the Company's stock will be delisted from the Shenzhen Stock Exchange.